Medical management of Peyronie's disease

Journal of Andrology

Volumn 30, Issue 4, 2009, Pages 397-405

  Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Erectile dysfunction; Penile curvature; Penis

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA2A INTERFERON; ALPHA2B INTERFERON; COLCHICINE; COLLAGENASE; LEVACECARNINE; PLACEBO; TAMOXIFEN; TOCOPHEROL; VERAPAMIL;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; PEYRONIE DISEASE; PRIORITY JOURNAL; SEXUAL INTERCOURSE;

4-AMINOBENZOIC ACID; ACETYLCARNITINE; ADRENAL CORTEX HORMONES; ADULT; COLCHICINE; COLLAGENASES; ERECTILE DYSFUNCTION; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; METALLOPROTEINS; PENILE INDURATION; TAMOXIFEN; TOCOPHEROLS; VERAPAMIL;

EID: 68549092646     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.006221     Document Type: Conference Paper

References (53)

1. Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie's disease. Int J Impot Res. 1999;11(4):207-212.
2. Bartsch G, Menander-Huber KB, Huber W, Marberger H. Orgotein, a new drug for the treatment of Peyronie's disease. Eur J Rheumatol Inflamm. 1981;4(2):250-259. (Pubitemid 11068221)
3. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease. J Sex Med.. 2007;4:1527-1538.
4. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88(1):63-67. (Pubitemid 33755042)
5. Bjekic MD, Vlajinac HO, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: a case-control study. BJU Int. 2006;97(3):570-574.
6. Bodner H, Howard AH, Kaplan JH. Peyronie's disease; cortisonehyaluronidase-hydrocortisone therapy. Trans West Sect Am Urol Assoc. 1953;20:32-35.
7. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol. 2006;3(2):111-115; quiz 116.
8. Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Vigili G, Storti L, Vespasiani G. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int. 2003;91(9):825-829. (Pubitemid 36724069)
9. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giuroli A, Jannini EA, Vepasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol. 2004;171(4):1605-1608. (Pubitemid 38365431)
10. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89-94.
11. Fitch WP, Easterling J, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCI, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease - a placebo-controlled pilot study. J Sex Med. 2007;4(2):477-484. (Pubitemid 46394721)
12. Gelbard M, Lindner A, Chvapil M, Kaufman J. Topical beta- aminopropionitrile in the treatment of Peyronie's disease. J Urol. 1983;129(4):746-748.
13. Gelbard M, Walsh R, Kaufman JJ. Clostridial collagenase and Peyronie disease [letter]. Urology. 1980;15(5):536..
14. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol. 1990;144(6):1376-1379.
15. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol. 1985;134(2):280-283. (Pubitemid 15006547)
16. Gustafson H, Johansson B, Edsmyr F. Peyronie's disease: experience of local treatment with orgotein. Eur Urol. 1981;7(6):346-348. (Pubitemid 11004702)
17. Hamilton RG, Mintz GR, Gelbard MK. Humoral immune responses in Peyronie's disease patients receiving clostridial collagenase therapy. J Urol. 1986;135(3):641-647.
18. Hauck EW, Bschleipfer T, Haag SM, Rohde V, Weidner W. Assessment among German urologists of various conservative treatment modalities for Peyronie's disease: results of a survey [in German]. Urol A. 2005;44:1189-1196. (Pubitemid 41456046)
19. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, Venable D, Honig S, McCullough A, Hakim LS, Nehra A, Templeton LE, Pryor JL. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006;176(1):394-398. (Pubitemid 43833173)
20. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol. 1997;79(1):40-42. (Pubitemid 28318842)
21. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease; results of a large survey. BJU Int. 2001;88(7):727-730. (Pubitemid 33755117)
22. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12(3):169-175.
23. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie's disease. Curr Opin Urol 2004;14(6):381-388. (Pubitemid 39506933)
24. Lemourt OM, Filgueiras LE, Rodriguez BA, Gonzalez OE, Bordonado R. Clinical evaluation of the use of propoleum in Peyronie's disease [in Spanish]. Arch Esp Urol. 1998;51:171-176.
25. Lemourt OM, Rodriguez BA, Puente GM, Vega GC, Navarro CM, Perez MA. Propoleum and Peyronie's disease [in Spanish]. Arch Esp Urol. 2003;56:805-813.
26. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169(5):1775-1778. (Pubitemid 36443494)
27. Levine LA, Greenfield JM. Establishing a standardized evaluation of the man with Peyronie's disease. Int J Impot Res. 2003;15(5 suppl):103-2S..
28. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994;151(6):1522-1524.
29. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002;168(6):2483-2485. (Pubitemid 35402645)
30. Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology. 1983;21(6):584-585.
31. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res. 2002;14:397-405. (Pubitemid 35285291)
32. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171(6 pt 1):2350-2353. (Pubitemid 38625468)
33. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006;175(6):2115-2118; discussion 2118. (Pubitemid 43668536)
34. Polat O, Gul O, Ozbey I, Ozdikici M, Bayraktar Y. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol. 1997;29(4):465-471. (Pubitemid 27496174)
35. Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie's disease). Int Urol Nephrol. 1993;25(2):169-172. (Pubitemid 23280787)
36. Pryor JP, Farrell CF. Controlled clinical trial of vitamin E in Peyronie's disease. Prog Reprod Biol. 1983;9:41-45.
37. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology. 2004;64(2):399-404. (Pubitemid 39092491)
38. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992;70(6):648-651.
39. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998;51(4):620-626. (Pubitemid 28186217)
40. Revelli G, Marino B, Piccoli F, Vitale L, Kiss A, Rossi R, Lanfranchi M, Drago GW. La Peyronie's disease: our experience [in Italian]. Minerva Chir. 1990;45:47-50. (Pubitemid 20133003)
41. Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93:5478-5482. (Pubitemid 26159475)
42. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann N Y Acad Sci. 1949;52:390-401.
43. Schieroni MP, Revello MP, Colombo M, Randone DF, Rolle L. Orgotein iontophoresis in the therapy of induratio penis plastica [in Italian]. Minerva Med. 1985;76(22-23):1085-1088.
44. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001;88(7):727-730. (Pubitemid 33755117)
45. Taylor FL, Levine LA. Non-surgical therapy of Peyronie's disease. Asian J Androl. 2008;10(1):79-87.
46. Teloken C, Rhoden EL, Grazziotin TM, Ross CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999;162(6):2003-2005.
47. Traber MG, Vitamin E. In: Shils ME, Olson JA, Shike M, & Ross AC eds. Modern Nutrition in Health and Disease. 10th ed. Baltimore, MD: Williams & Wilkins; 1999;347-362.
48. Tranchant C, Braun S, Warter JM. Mechanism of action of glucocorticoids: role of lipocortins [in French]. Rev Neurol. 1989;145:813-818. (Pubitemid 20013683)
49. Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J. 2003;79:449-453.
50. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-535. (Pubitemid 40357904)
51. Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol. 1970;103(1):75-76.
52. Winter CC, Khanna R. Peyronie's disease: results with dermojet injection of dexamethasone. J Urol. 1975;114(6):898-900.
53. Zarafonetis CJD, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J Urol. 1959;81:770-772.